Sep. 12 at 5:09 PM
$QTRX this has been an absolute disaster of an investment over the years. Thankfully made bank on the run over
$80-
$90 in the COVID years. But it’s been a painful ride down. Looks like it might be finally breaking out above its long downtrend line. If they can actually stabilize the revenue and get to cash flow breakeven, I think it can be worth 3x-4x revenue, or
$15. I’ve built up an overweight position again here below
$5.
Reimbursement price for their LucentAD test was announced this week at
$897, I believe above market expectations and well above feared levels.
There is also a prospect to seeing their reagent kits used in a significantly larger base of non Quanterix equipment. Reagents are where the margins are.
Perhaps this is finally the bottom???
